First Human Treated with Gene Therapy Aimed at Reversing Cellular Ageing
A world-first gene therapy has been administered to a human, targeting the reversal of ageing in cells. The trial focuses on retinal cells to improve vision, and if proven safe, could pave the way for a new class of rejuvenation therapies.
A Breakthrough in Cellular Rejuvenation
For the first time, a human has received a highly anticipated gene therapy designed to turn back the clock on ageing cells. The treatment is initially being tested on retinal cells, with the hope that encouraging them to behave as if they were young again could improve sight in affected patients.
This trial marks a significant step in the emerging field of cellular rejuvenation, which explores the potential to restore cellular function and potentially reverse aspects of ageing. If the therapy proves safe, it could open the door to a wide range of treatments based on this principle.
To learn more about this cutting-edge research, Madeleine Finlay spoke with Ian Sample, science editor at The Guardian, and John Knoepfler, professor of cell biology and human anatomy at the University of California, Davis.
How It Works
The gene therapy aims to activate cells' intrinsic rejuvenation capacity. Initially applied to retinal cells due to their accessibility and link to age-related vision decline, the approach may later be extended to other tissues and organs.
Researchers caution that this is only the first step, and further studies are needed to confirm safety and efficacy. Nonetheless, it represents a major milestone in medicine, potentially reshaping our understanding of ageing.
